Boston, MA, United States of America

Zoe Yin

This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Sigilon Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zoe Yin. Retrieved from https://idiyas.com/inventor/zoe-yin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.8

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Zoe Yin’s Patent Work in Polymer Evaluation.

Introduction

Zoe Yin is an inventor associated with Boston, Massachusetts, and Sigilon Therapeutics, Inc. The supplied information identifies her as a woman and credits her with 1 patent.

Latest Patents

Yin’s listed patent is “Methods of Evaluating Small Molecule-Modified Polymers in Compositions.” It describes methods for evaluating polymer compositions modified with small-molecule compounds, including afibrotic compounds, and determining the concentration levels of those compounds.

Career Highlights

The available information connects Yin’s patent work with Sigilon Therapeutics, Inc. Her listed invention focuses on evaluating modified polymer compositions and measuring compound concentrations.

Collaborations

Richard Heidebrecht is identified as Yin’s coworker. The supplied information does not specify whether he collaborated on the patent.

Conclusion

Zoe Yin’s listed patent addresses methods for evaluating small-molecule-modified polymers and determining compound concentrations, reflecting her documented connection to innovation at Sigilon Therapeutics, Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…